-
1.发明授权1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders 失效1,3-二 - （取代苯基）-2-丙炔-1-酮及其用于治疗疾病的用途公开(公告)号：US07202247B2
公开(公告)日：2007-04-10
申请号：US10325087
申请日：2002-12-19
IPC分类号： C07C49/213 , C07D213/06 , C07D231/02 , A61K31/12
CPC分类号： C07D333/38 , C07D333/22
摘要： The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.
摘要翻译： 本发明涉及使用通式化合物的化合物，药物组合物和方法
-
2.发明授权公开(公告)号：US07897776B2
公开(公告)日：2011-03-01
申请号：US12148966
申请日：2008-04-23
IPC分类号： C07D421/00 , C07D207/00
CPC分类号： C07D401/12 , C07D207/48 , C07D405/12 , C07D417/12
摘要： Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein: X and Y are independently selected from —CH2— or —CH2—CH2—; Z is selected from S(O)m or Se(O)m and m is 0, 1 or 2; R1 is optionally substituted heteroaryl or heterocyclic; R2 is selected from the group consisting of hydrogen, C1-C6 straight alkyl, and C1-C6 branched alkyl, wherein all may be optionally substituted; and R3 and R4 are alkyl.
摘要翻译： 提供化合物，药物组合物和治疗或预防炎性病症，特别是哮喘的方法。 所述化合物具有通式I或其药学上可接受的盐，酯，前药或衍生物：其中：X和Y独立地选自-CH 2 - 或-CH 2 -CH 2 - ; Z选自S（O）m或Se（O）m，m为0,1或2; R1是任选取代的杂芳基或杂环; R 2选自氢，C 1 -C 6直链烷基和C 1 -C 6支链烷基，其中全部可以被任选取代; R3和R4是烷基。
-
3.发明授权Sulfonamide-substituted chalcone derivatives and their use to treat diseases 失效磺酰胺取代的查耳酮衍生物及其用于治疗疾病的用途公开(公告)号：US07173129B2
公开(公告)日：2007-02-06
申请号：US10863115
申请日：2004-06-07
申请人： Kimberly J. Worsencroft , Liming Ni , Zhihong Ye , Charles Q. Meng , M. David Weingarten , Jacob E. Simpson , James A. Sikorski
发明人： Kimberly J. Worsencroft , Liming Ni , Zhihong Ye , Charles Q. Meng , M. David Weingarten , Jacob E. Simpson , James A. Sikorski
IPC分类号： C07D413/00 , C07D419/00 , C07D239/02 , C07D403/00 , C07D405/00 , C07D409/00 , C07D411/00
CPC分类号： A61K31/55 , A61K31/18 , A61K31/397 , A61K31/4015 , A61K31/445
摘要： The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.
摘要翻译： 本发明涉及使用通式化合物或其药学上可接受的盐或酯的化合物，药物组合物和方法，其中取代基在本申请中定义。
-
公开(公告)号：US07094801B2
公开(公告)日：2006-08-22
申请号：US10324987
申请日：2002-12-19
申请人： James A. Sikorski , Charles Q. Meng , M. David Weingarten , Kimberly J. Worsencroft , Liming Ni
发明人： James A. Sikorski , Charles Q. Meng , M. David Weingarten , Kimberly J. Worsencroft , Liming Ni
IPC分类号： A61K31/38 , A61K31/40 , A61K31/535 , C07D333/56 , C07D409/00
CPC分类号： C07D207/333 , C07C45/63 , C07C47/575 , C07D209/12 , C07D213/50 , C07D231/12 , C07D233/64 , C07D235/18 , C07D239/26 , C07D239/52 , C07D241/12 , C07D249/08 , C07D257/04 , C07D261/08 , C07D277/24 , C07D307/28 , C07D307/46 , C07D307/80 , C07D333/22 , C07D333/38 , C07D333/56 , C07D409/10 , C07D409/12 , C07D413/12 , C07D471/04 , C07H15/203
摘要： The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.
摘要翻译： 本发明涉及使用通式化合物或其药学上可接受的盐或酯的化合物，药物组合物和方法，其中取代基在本申请中定义。
-
5.发明申请公开(公告)号：US20090270454A1
公开(公告)日：2009-10-29
申请号：US12148966
申请日：2008-04-23
IPC分类号： A61K31/454 , C07D401/12 , C07D417/12 , A61K31/4025 , C07D403/12 , A61P11/06
CPC分类号： C07D401/12 , C07D207/48 , C07D405/12 , C07D417/12
摘要： Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein:X and Y are independently selected from —CH2— or —CH2—CH2—; Z is selected from S(O)m or Se(O)m and m is 0, 1 or 2; R1 is optionally substituted heteroaryl or heterocyclic; R2 is selected from the group consisting of hydrogen, C1-C6 straight alkyl, and C1-C6 branched alkyl, wherein all may be optionally substituted; and R3 and R4 are alkyl.
摘要翻译： 提供化合物，药物组合物和治疗或预防炎性病症，特别是哮喘的方法。 所述化合物具有通式I或其药学上可接受的盐，酯，前药或衍生物：其中：X和Y独立地选自-CH 2 - 或-CH 2 -CH 2 - ; Z选自S（O）m或Se（O）m，m为0,1或2; R1是任选取代的杂芳基或杂环; R 2选自氢，C 1 -C 6直链烷基和C 1 -C 6支链烷基，其中全部可以被任选取代; 并且R 3和R 4是烷基。
-
公开(公告)号：US20080280974A1
公开(公告)日：2008-11-13
申请号：US12151919
申请日：2008-05-09
申请人： M. David Weingarten , Liming Ni , Zhihong Ye , Charles Q. Meng , Raymond Ng , Jim A. Sikorski
发明人： M. David Weingarten , Liming Ni , Zhihong Ye , Charles Q. Meng , Raymond Ng , Jim A. Sikorski
IPC分类号： A61K31/352 , C07D493/10 , A61P29/00 , A61P11/00
CPC分类号： C07D493/10
摘要： Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein Y, Z and R1-R12 are defined herein.
摘要翻译： 提供化合物，药物组合物和治疗或预防炎性病症，特别是哮喘的方法。 所述化合物是通式I，或其药学上可接受的盐，酯，前药或衍生物：其中Y，Z和R 1 -R 12在本文中定义。
-
7.发明授权Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality 失效提高血浆HDL胆固醇水平和提高HDL功能的化合物和方法公开(公告)号：US07183317B2
公开(公告)日：2007-02-27
申请号：US10886927
申请日：2004-07-08
IPC分类号： A61K31/255 , C07C323/00 , C07C229/00
CPC分类号： G01N33/92 , C07C323/20 , G01N2500/00 , G01N2500/10 , G01N2800/044
摘要： It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.
摘要翻译： 已经发现，普罗布考的某些选择的醚及其药学上可接受的盐或前药可用于增加循环HDL胆固醇。 这些化合物还可以通过（a）增加胆固醇酯的清除率，（b）增加对肝细胞表面受体的HDL-粒子亲和力或（c）增加apoAI-HDL的半衰期来改善HDL功能。
-
8.发明授权Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease 失效用于治疗包括关节炎，哮喘和冠状动脉疾病在内的疾病的酚类抗氧化剂公开(公告)号：US07271274B2
公开(公告)日：2007-09-18
申请号：US11111196
申请日：2005-04-20
IPC分类号： C07D317/10 , A61K31/335 , C07C309/00
CPC分类号： C07C323/20
摘要： The invention relates to compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds, wherein the compounds are of the following Formulas: or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein the substituents are defined in the application. The invention further provides methods of treatment of inflammatory disorders by administering the compounds.
摘要翻译： 本发明涉及化合物，包含该化合物的药物组合物和使用该化合物的方法，其中所述化合物具有下列通式：或其药学上可接受的盐，酯或前药，其中取代基在本申请中定义。 本发明进一步提供了通过施用化合物治疗炎症性疾病的方法。
-
9.发明授权Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality 失效提高血浆HDL胆固醇水平和提高HDL功能的化合物和方法公开(公告)号：US06881860B2
公开(公告)日：2005-04-19
申请号：US09833407
申请日：2001-04-11
IPC分类号： A61K31/7034 , A61K31/10 , A61K31/192 , A61K31/198 , A61K31/255 , A61P3/06 , C07C323/20 , G01N33/92 , C07C321/00
CPC分类号： G01N33/92 , C07C323/20 , G01N2500/00 , G01N2500/10 , G01N2800/044
摘要： It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.
摘要翻译： 已经发现，普罗布考的某些选择的醚及其药学上可接受的盐或前药可用于增加循环HDL胆固醇。 这些化合物还可以通过（a）增加胆固醇酯的清除率，（b）增加对肝细胞表面受体的HDL-粒子亲和力或（c）增加apoAI-HDL的半衰期来改善HDL功能。
-
10.发明授权公开(公告)号：US07078431B2
公开(公告)日：2006-07-18
申请号：US10443470
申请日：2003-05-21
申请人： Charles Q. Meng , Liming Ni , James A. Sikorski , Lee K. Hoong
发明人： Charles Q. Meng , Liming Ni , James A. Sikorski , Lee K. Hoong
IPC分类号： A61K31/38 , A61K31/36 , A61K31/435 , C07D409/00 , C07C49/213
CPC分类号： A61K31/381 , A61K9/0031 , A61K9/0034 , A61K9/1271 , A61K31/44 , A61K31/505 , A61K31/513 , A61K45/06 , C07D333/16 , C07D333/56 , C07D409/10 , C07D493/04 , A61K2300/00
摘要： It has been discovered certain 1,3-bis-(substituted-phenyl)-2-propen-1-ones, including compounds of formula (I) inhibit the expression of VCAM-1, and thus can be used to treat a patient with a disorder mediated by VCAM-1. Examples of inflammatory disorders that are mediated by VCAM-1 include, but are not limited to arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.
-
-
-
-
-
-
-
-
-
搜索结果
27 条记录 (耗时 0.085 秒)
